Luliconazole
Luzu (luliconazole) is a small molecule pharmaceutical. Luliconazole was first approved as Luzu on 2013-11-14. It is used to treat mycoses and tinea in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Luzu
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Luliconazole
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUZU | Bausch Health Companies | N-204153 RX | 2013-11-14 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| luzu | New Drug Application | 2020-04-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| mycoses | — | D009181 | B35-B49 |
| tinea | EFO_0007510 | D014005 | B35.4 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meconium aspiration syndrome | D008471 | EFO_1001037 | P24.0 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | 5 | — | — | — | 5 |
| Newborn respiratory distress syndrome | D012127 | P22 | — | 2 | — | — | — | 2 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | — | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | 1 | — | — | — | 1 |
| Bronchopulmonary dysplasia | D001997 | P27.8 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LULICONAZOLE |
| INN | luliconazole |
| Description | Luliconazole, trade names Luzu among others, is an imidazole antifungal medication. As a 1% topical cream, It is indicated for the treatment of athlete's foot, jock itch, and ringworm caused by dermatophytes such as Trichophyton rubrum, Microsporum gypseum and Epidermophyton floccosum.
|
| Classification | Small molecule |
| Drug class | systemic antifungals (miconazole type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N#C/C(=C1/SC[C@@H](c2ccc(Cl)cc2Cl)S1)n1ccnc1 |
Identifiers
| PDB | — |
| CAS-ID | 187164-19-8 |
| RxCUI | 1482680 |
| ChEMBL ID | CHEMBL2105689 |
| ChEBI ID | 34825 |
| PubChem CID | 3003141 |
| DrugBank | DB08933 |
| UNII ID | RE91AN4S8G (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 360 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more